- Roivant to Report Financial Results for the Fourth Quarter and Fiscal Year Ended March 31, 2024, and Provide Business Update on Thursday, May 30, 2024
- Roivant Announces Positive NEPTUNE Study Results for Brepocitinib in NIU, as well as Board Authorization for up to $1.5 Billion Share Repurchase Program, Including Repurchase of Entire Sumitomo Pharma Stake for $648 Million
- Roivant Reports Financial Results for the Third Quarter Ended December 31, 2023, and Provides Business Update
- Roivant to Report Financial Results for the Third Quarter Ended December 31, 2023, and Provide Business Update on Tuesday, February 13, 2024
- Roivant Reports Positive Initial Phase 2 Results for Batoclimab in Graves’ Disease
- Roche Completes Acquisition of Telavant from Roivant, Including Rights to Novel TL1A Directed Antibody (RVT-3101) for the Treatment of Inflammatory Bowel Disease
- Roivant Announces Positive IMVT-1402 Initial 600 mg MAD Results that Confirm Best-in-Class Potential
- Roivant and Priovant Announce Results from Phase 2 Study of Oral Brepocitinib in Systemic Lupus Erythematosus
- Roivant Reports Financial Results for the Second Quarter Ended September 30, 2023, and Provides Business Update
- Roivant Announces Appointment of Mayukh Sukhatme to Its Board of Directors
More ▼
Key statistics
On Thursday, Roivant Sciences Ltd (ROIV:NSQ) closed at 11.41, -13.82% below its 52-week high of 13.24, set on Sep 28, 2023.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 11.48 |
---|---|
High | 11.48 |
Low | 11.34 |
Bid | 11.00 |
Offer | 11.65 |
Previous close | 11.41 |
Average volume | 3.34m |
---|---|
Shares outstanding | 805.85m |
Free float | 627.01m |
P/E (TTM) | 2.20 |
Market cap | 8.97bn USD |
EPS (TTM) | 5.07 USD |
Data delayed at least 15 minutes, as of May 16 2024 21:15 BST.
More ▼